Key result
Ticlopidine administered at 500 mg every 12 hours for 3 days in healthy volunteers significantly suppressed platelet aggregation and adhesiveness (p<0.05) without affecting blood clotting.
Why the study?
Does ticlopidine affect platelet function, blood coagulation, and safety in healthy volunteers?
Population
6 healthy volunteers
Design
Other
Follow-up
3 days
Authors
Loading...
Should not yet change practice; hypothesis-generating for ticlopidine as an antithrombotic agent in patients.
Does ticlopidine affect platelet function, blood coagulation, and safety in healthy volunteers?
p-value: p=<0.05
Ticlopidine demonstrates safe and effective suppression of platelet aggregation in healthy volunteers, supporting its potential as an antithrombotic agent.
Ebihara et al. (1978) studied Healthy volunteers (n=6). Ticlopidine vs. Baseline (pre-administration) was evaluated on Platelet aggregation and adhesiveness (p=<0.05). Ticlopidine administered at 500 mg every 12 hours for 3 days in healthy volunteers significantly suppressed platelet aggregation and adhesiveness (p<0.05) without affecting blood clotting.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: